ArticleFrontiers in oncology2023

Cost-effectiveness of analysis serplulimab plus chemotherapy as first-line therapy for PD-L1-positive advanced esophageal squamous cell carcinoma.

Hanrui Zheng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.